# Section 1: Company Overview

## S1.1: Basic Information

| Field | Value |
| :---- | :---- |
| Company Name | PolyNovo Limited |
| Establishment Date | N/A |
| Headquarters Location | Port Melbourne, Australia |


## S1.2 : Core Competencies

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Innovation Advantages | PolyNovo leverages surgeon-led insights to drive innovation in its product pipeline, including line extensions and new graftable and implantable devices. The company invests in R&D to support new product development and faster commercialisation, with a focus on building clinical evidence and health economic outcomes research. The NovoSorb SynTrix platform serves as a foundation for developing plastics and reconstructive device products, sharing manufacturing processes and technology across applications. The company also utilises digital tools such as an online learning platform for employee development and professional education programs like 'Science of Complex Wound Management'. | PolyNovo demonstrates strong capabilities in research and development, focusing on the proprietary NovoSorb resorbable polymer platform with flexible configurations including foams, filaments, films, and woven structures. The company has developed innovative products such as NovoSorb BTM and NovoSorb MTX, with the latter receiving FDA 510(k) clearance in 2022, expanding applications in soft tissue regeneration. PolyNovo invests in clinical trials, including a BARDA-funded pivotal trial for full thickness burns and a diabetic foot ulcer trial, and maintains a robust ESG framework integrating environmental, social, and governance factors into its operations. |
| Product Advantages | PolyNovo's core product is the NovoSorb Biodegradable Temporising Matrix (BTM), which offers significant health economic benefits, robustness against infection, and reduces the need for scar revision surgery. The product portfolio includes NovoSorb MTX, a soft tissue reconstruction platform with FDA 510(k) clearance, and SUPRATHEL®, an epidermal substitute with advantages such as pain relief, low infection rates, fast wound healing, and excellent cosmetic outcomes. The NovoSorb SynTrix platform supports development of hernia and other tissue reinforcement devices. The company is expanding product indications and geographic registrations, including new markets in Asia and Latin America. | PolyNovo's product portfolio centers on NovoSorb BTM and NovoSorb MTX, addressing a broad range of clinical indications including burns, acute and chronic wounds, limb salvage, necrotising fasciitis, and soft tissue reconstruction. The company is developing implantable applications such as surgical mesh products for hernia repair, abdominal wall reconstruction, and breast reconstruction, leveraging shared manufacturing processes and technology. NovoSorb MTX complements BTM by providing a product for wound management without a sealing membrane, suitable for partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, and surgical wounds. |
| Brand Recognition | PolyNovo is recognized as the category leader in burn procedures in multiple developed markets including the U.S., U.K., Germany, Australia, and New Zealand. The company maintains long-term relationships with surgeons and health systems, supported by professional education and clinical evidence. NovoSorb BTM is widely adopted in burns units and major treatment centers, with strong market leadership in difficult burns and soft tissue reconstruction. The company has established a global presence with products available in over 41 countries and is expanding into new geographies such as Japan, China, and Brazil. Partnerships with government agencies like BARDA and inclusion in government procurement portals (e.g., India's Government-e-Marketplace) further enhance its market position. | PolyNovo is recognized by surgeons as a next-generation standard of care for burn treatment, with growing acceptance and surgeon-led innovation driving global sales growth. The company has established long-term relationships with burn centers and hospitals across multiple geographies including the U.S., UK, Europe, Australia, Canada, India, and Hong Kong. PolyNovo's products are supported by clinical education and high-quality published clinical data, and the company has expanded its sales teams significantly, particularly in the U.S., to support market penetration and account growth. |
| Reputation Ratings | PolyNovo maintains a robust Environmental, Social, and Governance (ESG) framework, including carbon-neutral certification for its Australian operations in FY23 and adherence to best practice bioethics principles. The company has updated its Diversity Policy with targets for female representation and conducted gender pay equity analysis. It enforces a zero-tolerance approach to modern slavery and provides staff training on the issue. Health and safety policies emphasize injury prevention, with zero lost time injuries reported in FY24. Corporate governance aligns with the ASX Corporate Governance Council's eight principles, supported by comprehensive policies on ethics, risk management, and disclosure. The company’s FY23 Modern Slavery Statement and other governance documents are publicly available on its website. | PolyNovo maintains a comprehensive ESG approach with carbon neutral certification for business operations in FY2021-22 under assessment by Climate Active. The company adheres to high standards of corporate governance aligned with the ASX Corporate Governance Council's eight principles, including policies on commercial code of conduct, gender diversity, modern slavery, and health and safety. PolyNovo commits to best practice bioethics in clinical trials, uses environmentally certified waste disposal providers, and has a zero lost time injury record in FY23. The company also complies with Australian Accounting Standards and International Financial Reporting Standards. |


## S1.3 : Mission & Vision

| Field | Value |
| :---- | :---- |
| Mission Statement | Our mission is to innovate and bring disruptive technologies to market by partnering with the best minds to improve patient outcomes and reimagine the standard of care. |
| Vision Statement | Healing. Redefined. |
| Core Values | We put patients first, We earn trust, We innovate boldly, We believe in each other, We respect and nurture diversity |


# Section 2: Financial Performance

## S2.1: Income Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Revenue | 104,763.0 | 66,535.0 | 41,890,603.0 | Thousands | AUD |
| Cost of Goods Sold | N/A | (4,933,513.0) | (2,548,746.0) | Thousands | AUD |
| Gross Profit | N/A | (4,866,978.0) | 39,341,857.0 | Thousands | AUD |
| Operating Expense | 95,990.0 | 66,120.0 | 40,492,781.0 | Thousands | AUD |
| Operating Income | N/A | (4,933,098.0) | (1,150,924.0) | Thousands | AUD |
| Net Profit | 5,261.0 | (4,924.0) | (1,192,532.0) | Thousands | AUD |
| Income before income taxes | 1,711.0 | (4,933.0) | (1,150,924.0) | Thousands | AUD |
| Income tax expense(benefit) | (3,550.0) | 9.0 | 41,608.0 | Thousands | AUD |
| Interest Expense | 721.0 | 714.0 | 315,366.0 | Thousands | AUD |


## S2.2: Balance Sheet

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Total Assets | 108,720.0 | 92,621.0 | N/A | Thousands | AUD |
| Current Assets | 79,295.0 | 67,354.0 | N/A | Thousands | AUD |
| Non-Current Assets | 29,425.0 | 25,267.0 | N/A | Thousands | AUD |
| Total Liabilities | 36,596.0 | 27,238.0 | N/A | Thousands | AUD |
| Current Liabilities | 23,247.0 | 12,668.0 | N/A | Thousands | AUD |
| Non-Current Liabilities | 13,349.0 | 14,570.0 | N/A | Thousands | AUD |
| Shareholders' Equity | 72,124.0 | 65,383.0 | N/A | Thousands | AUD |
| Retained Earnings | (116,117.0) | (121,378.0) | N/A | Thousands | AUD |
| Total Equity and Liabilities | 108,720.0 | 92,621.0 | N/A | Thousands | AUD |
| Inventories | 8,972.0 | 4,530.0 | N/A | Thousands | AUD |
| Prepaid Expenses | 3,301.0 | 1,903.0 | N/A | Thousands | AUD |


## S2.3: Cash Flow Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Net Cash Flow from Operations | 3,683.0 | (6,612,528.0) | (2,057,034.0) | Thousands | AUD |
| Net Cash Flow from Investing | (1,490.0) | (848,768.0) | 5,858,471.0 | Thousands | AUD |
| Net Cash Flow from Financing | (3,170.0) | 48,064,381.0 | (5,388,314.0) | Thousands | AUD |
| Net Increase/Decrease in Cash | (977.0) | 40,603,085.0 | (1,586,877.0) | Thousands | AUD |
| Dividends | N/A | N/A | N/A | N/A | N/A |


## S2.4: Key Financial Metrics

|       | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Gross Margin | N/A | 7514.91% | 106.08% |
| Operating Margin | N/A | (7414.29%) | (2.75%) |
| Net Profit Margin | 5.02% | (7.40%) | (2.85%) |
| Current Ratio | 341.10% | 531.69% | N/A |
| Quick Ratio | 288.30% | 480.90% | N/A |
| Debt-to-Equity | 50.74% | 41.66% | N/A |
| Interest Coverage | N/A | (690910.08%) | (364.95%) |
| Asset Turnover | 104.07% | N/A | N/A |
| Return on Equity | 7.65% | N/A | N/A |
| Return on Assets | 5.23% | N/A | N/A |
| Effective Tax Rate | (207.48%) | (0.18%) | (3.62%) | 
| Dividend Payout Ratio | N/A | N/A | N/A |


## S2.5: Operating Performance

| Field | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Revenue by Product/Service | Commercial product sales: $92,042,000, BARDA revenue: $11,150,000 | Commercial product sales: $59,578,000, BARDA revenue: $5,663,000 | Commercial product sales: $37,643,160, BARDA revenue: $3,796,679 |
| Revenue by Geographic Region | United States of America: $79,836,000, Australia and New Zealand: $6,560,000, Other countries: $16,796,000 | United States of America: $51,764,000, Australia and New Zealand: $4,769,000, Other countries: $8,709,000 | United States of America: $35,857,273, Australia and New Zealand: $3,206,724, Other countries: $2,375,842 |


# Section 3: Business Analysis

## S3.1: Profitability Analysis

| Field | Answer |
| :---- | :---- |
| Revenue & Direct-Cost Dynamics | PolyNovo Limited's revenue shows a declining trend from AUD 41,890,603 thousand in 2022 to AUD 66,535 thousand in 2023 and further down to AUD 104,763 thousand in 2024, indicating a significant drop in reported revenue figures likely due to a change in reporting scale or business scope. Gross margin data is inconsistent, with an extremely high gross margin of 7514.91% in 2023 and 106.08% in 2022, but unavailable for 2024, suggesting possible anomalies or restatements in cost of goods sold or revenue recognition. Revenue by product/service shows steady growth in commercial product sales from AUD 37,643,160 thousand in 2022 to AUD 92,042,000 in 2024, and BARDA revenue also increased from AUD 3,796,679 thousand in 2022 to AUD 11,150,000 in 2024. Geographically, the United States remains the dominant market, growing from AUD 35,857,273 thousand in 2022 to AUD 79,836,000 in 2024, with Australia and New Zealand and other countries also showing growth but at a smaller scale. |
| Operating Efficiency | Operating margin deteriorated sharply from (2.75%) in 2022 to (7414.29%) in 2023, with no data for 2024, reflecting significant operating losses relative to revenue in 2023. Operating income was negative in 2022 at (1,150,924) thousand AUD and worsened to (4,933,098) thousand AUD in 2023, indicating increased operating inefficiency despite revenue growth in commercial sales. Operating expenses decreased substantially from AUD 40,492,781 thousand in 2022 to AUD 66,120 thousand in 2023 and AUD 95,990 thousand in 2024, suggesting aggressive cost management or restructuring efforts. However, the negative operating income despite lower expenses in 2023 points to possible issues in cost of goods sold or other operational challenges. |
| External & One-Off Impact | The effective tax rate swung dramatically from (3.62%) in 2022 to (0.18%) in 2023 and then to a negative (207.48%) in 2024, indicating unusual tax benefits or adjustments impacting net profitability. Income tax expense was positive AUD 41,608 thousand in 2022, negligible at 9 thousand in 2023, and negative at (3,550) thousand in 2024, further supporting the presence of tax credits or refunds. Non-recurring items are not explicitly listed, and no external factors affecting profitability are explicitly mentioned in the provided data. |


## S3.2: Financial Performance Summary

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Comprehensive financial health | In 2024, PolyNovo Limited demonstrated an improved financial position compared to 2023. Total assets increased from AUD 92,621 thousand to AUD 108,720 thousand, driven by growth in both current assets (from AUD 67,354 thousand to AUD 79,295 thousand) and non-current assets (from AUD 25,267 thousand to AUD 29,425 thousand). Total liabilities rose from AUD 27,238 thousand to AUD 36,596 thousand, primarily due to a significant increase in current liabilities (from AUD 12,668 thousand to AUD 23,247 thousand), while non-current liabilities slightly decreased. Shareholders' equity strengthened from AUD 65,383 thousand to AUD 72,124 thousand, reflecting retained earnings improving from a negative AUD 121,378 thousand to a less negative AUD 116,117 thousand. The current ratio decreased from 531.69% to 341.10%, indicating a reduction in liquidity but still a strong ability to cover short-term obligations. The debt to equity ratio increased from 41.66% to 50.74%, suggesting a modest rise in leverage but still a moderate capital structure. Overall, the company’s financial health in 2024 shows asset growth and equity strengthening, with manageable increases in liabilities and solid liquidity levels. | In 2023, PolyNovo Limited reported total assets of AUD 92,621 thousand, with current assets comprising AUD 67,354 thousand and non-current assets AUD 25,267 thousand. Total liabilities stood at AUD 27,238 thousand, split between current liabilities of AUD 12,668 thousand and non-current liabilities of AUD 14,570 thousand. Shareholders' equity was AUD 65,383 thousand, indicating a solid equity base relative to liabilities. The current ratio was 531.69%, reflecting very strong short-term liquidity and an ability to cover current liabilities multiple times over. The debt to equity ratio was 41.66%, suggesting a moderate level of leverage and a balanced capital structure with equity financing predominating. Retained earnings were negative at AUD (121,378) thousand, which may reflect accumulated losses or distributions. Overall, the company’s financial health in 2023 shows strong liquidity and a conservative leverage position, supported by a robust equity base despite negative retained earnings. |
| Profitability and earnings quality | PolyNovo Limited’s profitability improved markedly in 2024. Revenue surged by 57.4% from AUD 66,535 thousand in 2023 to AUD 104,763 thousand in 2024, driven by higher commercial product sales (up from AUD 59,578 thousand to AUD 92,042 thousand) and BARDA revenue (nearly doubling from AUD 5,663 thousand to AUD 11,150 thousand). Net profit turned positive at AUD 5,261 thousand compared to a net loss of AUD 4,924 thousand in 2023. Income before taxes also improved from a loss of AUD 4,933 thousand to a profit of AUD 1,711 thousand. The net profit margin shifted from a negative 7.40% to a positive 5.02%, indicating enhanced earnings quality. Operating expenses increased from AUD 66,120 thousand to AUD 95,990 thousand, but without 2024 cost of goods sold data, gross and operating margins cannot be precisely assessed. Return on equity and assets were reported at 7.65% and 5.23% respectively, reflecting effective utilization of equity and assets to generate profits. The effective tax rate was negative at -207.48%, influenced by a tax benefit of AUD 3,550 thousand, which may reflect deferred tax assets or tax credits. Overall, 2024 shows a strong turnaround in profitability and earnings quality for PolyNovo Limited. | PolyNovo's revenue in 2023 was AUD 66,535 thousand, showing a significant decrease compared to AUD 41,890,603 thousand in 2022, indicating a major contraction or possible data inconsistency. Cost of goods sold increased to AUD (4,933,513) thousand from AUD (2,548,746) thousand in 2022, resulting in a gross loss of AUD (4,866,978) thousand compared to a gross profit of AUD 39,341,857 thousand in 2022. Operating expenses were AUD 66,120 thousand, a sharp decrease from AUD 40,492,781 thousand in 2022. Operating income was a loss of AUD (4,933,098) thousand, worsening from a loss of AUD (1,150,924) thousand in 2022. Net profit was a small loss of AUD (4,924) thousand, improved from a loss of AUD (1,192,532) thousand in 2022. Margins show extreme volatility: gross margin at 7514.91%, operating margin at (7414.29%), and net profit margin at (7.40%), which appear inconsistent with reported losses and may reflect data anomalies. Effective tax rate was minimal at (0.18%). Overall, profitability deteriorated sharply at the gross and operating levels but net loss narrowed significantly, suggesting possible non-operating income or adjustments. Earnings quality appears unstable with large swings in costs and revenues. |
| Operational efficiency | Operational efficiency in 2024 improved significantly. The asset turnover ratio was high at 104.07%, indicating very efficient use of assets to generate revenue. Revenue growth outpaced the increase in operating expenses, suggesting some control over cost escalation despite operating expenses rising by 45.2%. Inventories nearly doubled from AUD 4,530 thousand to AUD 8,972 thousand, which may indicate increased production or stockpiling in anticipation of demand. Net cash from operations turned positive at AUD 3,683 thousand compared to a large negative cash flow of AUD 6,612,528 thousand in 2023, signaling a substantial improvement in cash generation from core business activities. Working capital increased as current assets grew faster than current liabilities, although the current ratio declined, reflecting a tighter but still strong liquidity position. Net cash from investing activities was negative but modest at AUD (1,490) thousand, indicating controlled investment spending. Overall, operational efficiency improved with better asset utilization, positive operating cash flow, and manageable working capital dynamics. | Operationally, PolyNovo experienced a large negative net cash flow from operations of AUD (6,612,528) thousand in 2023, worsening from AUD (2,057,034) thousand in 2022, indicating cash outflows from core business activities. Net cash used in investing activities was AUD (848,768) thousand, a reversal from positive investing cash flow of AUD 5,858,471 thousand in 2022, suggesting increased investment or asset purchases. Net cash from financing activities was strongly positive at AUD 48,064,381 thousand, a significant turnaround from a cash outflow of AUD (5,388,314) thousand in 2022, indicating substantial financing inflows, possibly from equity or debt issuance. Inventories were AUD 4,530 thousand. The current ratio of 531.69% indicates excellent liquidity and working capital management. However, the negative operating cash flow and large financing inflows suggest operational inefficiencies and reliance on external funding. Asset turnover and other utilization metrics are unavailable, limiting deeper analysis. |
| Financial risk identification and early warning | Financial risk indicators in 2024 show some areas of caution but no immediate distress. The debt to equity ratio increased to 50.74% from 41.66%, indicating higher leverage and potential increased financial risk. Current liabilities nearly doubled, which contributed to a lower current ratio of 341.10% from 531.69%, though liquidity remains strong. Interest expense remained stable at AUD 721 thousand, but interest coverage data for 2024 is unavailable, limiting assessment of the company’s ability to service debt from operating income. The effective tax rate was significantly negative at -207.48%, which may reflect tax benefits but also introduces variability in tax expense. The large negative retained earnings balance, although improved, still signals accumulated losses historically. No dividends were paid in 2024, which may reflect a conservative approach to preserving cash. Overall, while leverage and current liabilities increased, the company maintains strong liquidity and improved profitability, mitigating immediate financial risk concerns but warranting monitoring of leverage and tax impacts. | Financial risk indicators in 2023 show a moderate debt to equity ratio of 41.66%, indicating manageable leverage. Interest expense was low at AUD 714 thousand, with an extremely high interest coverage ratio of 690,910.08%, suggesting the company easily covers interest obligations, though this figure may be distorted by low or negative operating income. The effective tax rate was very low at (0.18%), indicating minimal tax burden or possible tax credits. Liquidity is strong with a current ratio of 531.69%, reducing short-term liquidity risk. However, the large negative operating cash flow and reliance on substantial financing inflows (AUD 48,064,381 thousand) may pose refinancing or sustainability risks. Negative retained earnings of AUD (121,378) thousand could signal accumulated losses. Overall, financial risk appears moderate with strong liquidity and low leverage but operational cash flow weakness and unusual financing activity warrant close monitoring. |
| Future financial performance projection | Looking ahead, PolyNovo Limited’s financial performance appears poised for continued growth supported by strong revenue expansion and improved profitability in 2024. The company’s investment activity was modest with net cash used in investing at AUD (1,490) thousand, suggesting cautious capital expenditure. The positive net cash from operations of AUD 3,683 thousand indicates sustainable cash flow generation to support operations and potential future investments. No dividends were declared, implying a focus on reinvestment or debt reduction. Revenue growth was broad-based across product lines and geographic regions, with the United States market expanding significantly from AUD 51,764 thousand to AUD 79,836 thousand, and other countries nearly doubling revenue, indicating diversified growth opportunities. The increase in inventories may support anticipated demand growth. The company’s improved equity base and manageable leverage provide a solid foundation for future financing needs. Overall, PolyNovo Limited is positioned for sustainable financial performance with growth prospects supported by operational cash flow and expanding markets. | Looking ahead, PolyNovo's significant net cash inflow from financing activities (AUD 48,064,381 thousand) in 2023 provides a strong liquidity buffer and potential capital for investment or debt repayment. However, negative net cash from operations (AUD (6,612,528) thousand) and investing cash outflows (AUD (848,768) thousand) raise concerns about cash flow sustainability from core operations. No dividends were declared, indicating a conservative dividend policy or reinvestment focus. Revenue by product shows commercial product sales at AUD 59,578,000 and BARDA revenue at AUD 5,663,000, with geographic revenue concentrated in the USA (AUD 51,764,000), Australia and New Zealand (AUD 4,769,000), and other countries (AUD 8,709,000), suggesting growth opportunities in diverse markets. The company’s future performance will likely depend on improving operational cash flows and leveraging strong financing to support growth initiatives. Continued monitoring of cash flow trends and profitability is essential for sustainable financial performance. |


## S3.3: Business Competitiveness

| Field | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Business Model | The company's primary business model is the design, manufacturing, and sale of biomedical devices, specifically based on its proprietary NovoSorb bioabsorbable polymer technology. Revenue is primarily generated through commercial product sales of NovoSorb Biodegradable Temporising Matrix (BTM) and derivative products, recognized at the point in time when control transfers to the customer or distributor. The company also generates revenue from research and development services, notably through a contract with the Biomedical Advanced Research and Development Authority (BARDA) for clinical trials and product development, with revenue recognized over time based on input measures of specified costs. The company sells directly in key markets including Australia, Hong Kong, India, Ireland, New Zealand, Singapore, United Kingdom, and the United States, and uses a distributor model in other territories such as Canada, Europe, Taiwan, and South Africa. The business model includes ongoing investment in research and development to expand product offerings and indications, as well as capacity expansion to meet growing global demand. | PolyNovo Limited operates primarily as a designer, manufacturer, and seller of biomedical devices based on its proprietary bioabsorbable polymer technology called NovoSorb. The company's main revenue is generated through commercial product sales, particularly of its flagship product NovoSorb Biodegradable Temporising Matrix (BTM), which is sold directly in several countries and through distributors in others. Revenue is recognized at the point of product delivery to customers or distributors. Additionally, PolyNovo generates revenue from research and development services under contracts such as the BARDA agreement, where revenue is recognized over time based on progress in clinical trials and development milestones. The company also receives government grants supporting manufacturing capacity and equipment development. Key products include NovoSorb BTM for wound healing and NovoSorb MTX, a product innovation for soft tissue regeneration with FDA 510(k) clearance. The business model focuses on expanding product offerings, entering new geographic markets, and leveraging clinical education and surgeon advocacy to drive sales growth. The company invests heavily in R&D, clinical trials, and sales and marketing to support commercialization and global expansion. |
| Market Position | PolyNovo is a market leader in the burn care category in several developed geographies, including the U.S., U.K., Germany, Ireland, and Hong Kong. The company holds the leading market share in difficult burns and soft tissue reconstruction procedures in these regions. Specifically, in the U.K., NovoSorb BTM is used in all 24 burns units and 22 major treatment centers, establishing a market leader position for full-thickness burns. In Germany, the company has penetrated 98% of burn centers and is experiencing strong growth. The U.S. market is the largest for the company, with sales growth of 49.0% in AUD (45.6% in USD) and a revenue of A$68.7 million in FY24. The Rest of World (ROW) sales grew by 73.3%, with notable increases in Australia (38.7%), U.K./Ireland (81.5%), Germany (81.2%), and Hong Kong (107.2%). BARDA-related sales represent 11% of total sales revenue. The company is expanding into emerging markets such as India, where NovoSorb BTM has been included in the Government-e-Marketplace portal, facilitating adoption in government hospitals. The company is also pursuing entry into Japan, China, Mexico, and Egypt, and expects continued strong revenue growth in FY25. Overall, PolyNovo is positioned as a category leader with a strong competitive advantage due to its patented technology, clinical evidence, and broad geographic footprint. | PolyNovo is a market leader in the dermal implant and wound care segment, particularly with its NovoSorb BTM product, which has achieved significant surgeon acceptance and is recognized as the next generation standard of care for burn care and soft tissue reconstruction. The company has demonstrated strong sales growth globally, with FY23 NovoSorb BTM sales increasing by 58.3% to $59.6 million. In the U.S., sales grew 44.6% in AUD, and the Rest of World (ROW) sales increased by 133.9%. Specific market growth highlights include Australia up 84.3%, UK/Ireland up 168.8%, Germany up 192.8%, and strong sales in Canada and Hong Kong. The UK market has seen a 160.3% sales increase with NovoSorb BTM usage in all major trauma and burn centers, achieving market leadership in the burns segment. In Germany, the distributor covers 98% of burn centers. The company has over 600 customer accounts in direct markets, with the U.S. sales team growing from 54 to 93 and hospital accounts increasing from 189 to 299. PolyNovo has also entered new markets including India, Hong Kong, Canada, Spain, and France, with early sales success. The BARDA pivotal trial in the U.S. supports further market penetration. PolyNovo's competitive advantages include patented proprietary technology with superior biocompatibility, a broad product portfolio, strong clinical evidence, and a growing global sales and marketing infrastructure. The company is positioned as a market leader with expanding global reach and a strong growth trajectory. |


# Section 4: Risk Factors

## S4.1: Risk Factors

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Market Risks | The Company faces market risks including increased competition which may lead to loss of market share, and the risk that products may be superseded by medical advancements resulting in alternative treatments. Sales and revenue are unpredictable due to the nature of the medical device category. Inflation and rising interest rates have increased costs such as wages and salaries across all markets. Demand volatility is evident with strong sales growth in various regions but remains subject to market conditions. The Company mitigates these risks by strategic product development, expanding product range, geographic expansion including new registrations and market entries (e.g., Japan, Mexico, India), and investing in clinical education and sales force expansion. | PolyNovo faces market risks including volatility in demand and competition inherent in the biotechnology sector, which is highly speculative and driven by market sentiment. The company is dependent on the success of its research projects and its ability to attract funding, with no guarantee of access to capital. Inflation and rising interest rates have increased costs across all markets, including wages and salaries, impacting operational costs. The company operates in multiple international markets with varying economic conditions and currency exposures. The forward-looking statements caution that actual results may differ materially due to risks inherent in drug and medical device development and commercialization. Market expansion into new geographies such as India, Canada, Hong Kong, Spain, and France introduces risks related to market acceptance and regulatory approvals. The company mitigates some market risks by expanding its sales teams, leveraging surgeon advocacy, and pursuing regulatory clearances to support product portfolio expansion. |
| Operational Risks | Operational risks include reliance on a single manufacturing site which could disrupt supply if the site becomes inoperative; product quality failures that could lead to injury, litigation, recall, and reputational harm; reliance on suppliers for key materials which may cause delays or increased costs; and risks related to intellectual property theft or compromise. The Company mitigates these risks by constructing a third manufacturing facility to increase capacity and resilience, implementing a business continuity plan, maintaining business interruption insurance, storing finished products in multiple offsite warehouses, focusing on quality throughout product lifecycle, maintaining product liability insurance, working closely with suppliers to manage supply chain risks, diversifying suppliers, enforcing confidentiality agreements, limiting and monitoring system access, and maintaining an evolving patent and trademark portfolio with legal counsel support. | Operational risks include challenges in research, development, and commercialization of medical devices, which may materially impact financial performance and asset values. The company faces risks related to manufacturing scale-up, as evidenced by commissioning a second manufacturing facility and planning a new larger facility to meet increased demand. Supply chain and logistics risks exist due to global operations and reliance on distributors in certain regions. The company manages health and safety risks with a strong focus on injury prevention and continuous improvement, reporting zero lost time injuries in FY23. Human resources risks are managed through recruitment drives, especially in sales and marketing teams in the U.S. and new markets. Product development risks include clinical trial progress and regulatory approvals, with ongoing pivotal trials and FDA submissions. Quality and compliance risks are implied through regulatory approvals and clinical data requirements. Business continuity risks are managed by maintaining discretion over cash outflows and operational cash flow forecasting to respond to unexpected demands. |
| Financial Risks | Financial risks identified include interest rate risk, credit risk, liquidity risk, and foreign currency risk. Interest rate risk arises from fluctuations affecting cash holdings and finance facilities; mitigated by locking cash in term deposits with maturity aligned to cash flow forecasts. Credit risk arises from counterparty defaults on cash, cash equivalents, and receivables; mitigated by placing cash with highly rated banks, monitoring receivables, and low credit risk on BARDA income receivables. Liquidity risk involves difficulty in meeting financial liabilities; managed by Board oversight of cash flow forecasts, ensuring sufficient cash flow before entering contracts, and potential capital raising if needed. Foreign currency risk arises from exposure to multiple currencies (USD, GBP, EUR, NZD, etc.); mitigated by holding cash in multiple currencies and using foreign exchange forward contracts on an ad hoc basis. The Group maintains a formal risk management policy and framework overseen by the Board to manage these financial risks. | Financial risks identified include foreign currency risk due to exposure to multiple currencies (USD, NZD, EUR, CAD, INR, GBP, SGD) affecting cash, receivables, and payables. The company mitigates this by holding cash and equivalents in various foreign currencies matching its exposures. Interest rate risk arises from fluctuations in market interest rates impacting cash holdings and finance facilities; managed by locking portions of cash into term deposits with maturity aligned to cash flow forecasts. Credit risk arises from potential counterparty defaults on receivables and cash deposits; mitigated by placing cash with highly rated banks and monitoring receivables aging and expected credit losses, which remain low. Liquidity risk is managed by the Board through regular review of cash flow forecasts and ensuring sufficient cash to meet liabilities, with the ability to raise capital if needed. Capital risk is managed to maintain going concern and optimal capital structure, with the Board monitoring equity market conditions and cash flows. The company holds equipment finance facilities and short-term loans with defined interest rates and maturities. Expected credit losses on trade receivables are calculated using a provision matrix based on historical and forward-looking data. |
| Compliance Risks | Compliance risks include failure to comply with a wide range of legal and regulatory requirements related to products, sales, health and safety, employment, and corporate regulation. Non-compliance could negatively impact operations, customers, employees, and shareholders. The Company mitigates these risks through internal systems, processes, and monitoring, supported by dedicated teams in Quality Assurance, Regulatory Affairs, Medical Liaison, and Legal & Compliance. Compliance frameworks are evolving to address the changing complexity of obligations. Additionally, the Company adheres to bioethics standards in clinical trials, maintains product liability insurance, and enforces confidentiality and intellectual property protections. Environmental compliance is addressed through certified waste disposal, carbon emission reduction initiatives, and an Environment Policy. | Compliance risks include regulatory approvals and legal requirements for medical devices, with ongoing FDA 510(k) submissions and approvals necessary for product expansion. The company operates in multiple jurisdictions, each with specific regulatory environments, requiring adherence to local laws and standards. Environmental compliance is addressed through commitments to minimize environmental impact, waste management plans, and carbon neutrality certification for business operations. The company has policies addressing modern slavery and ethical labor practices in operations and supply chains. Corporate governance policies are in place to ensure ethical conduct, risk management, and legal compliance, overseen by the Board and various committees. Health and safety compliance is maintained with formal policies and zero injury records. The company complies with Australian Accounting Standards, IFRS, and the Corporations Act 2001. Indemnification and insurance policies are maintained for directors and officers to manage legal liabilities. |


# Section 5: Corporate Governance

## S5.1: Board Composition
| Name | Position | Total Income |
| :---- | :---- | -----------: |
| Mr Swami Raote | Chief Executive Officer | US$1,049,888 |
| Mr Jan Gielen | Chief Financial Officer | £338,584,000 |
| Dr David McQuillan | Chief Scientific Officer | US$265,188 |
| Mr Philip Scorgie | Chief Information Officer | £187,766,000 |
| Mr David Williams | Non-executive Chairman | N/A |
| Mr Lior Harel | General Counsel and Company Secretary | N/A |
| Mr David Morris | President, Asia Pacific | N/A |
| Mr Ed Graubart | President, North America | N/A |

## S5.2: Internal Controls
| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Risk assessment procedures | The Group has a formal risk management policy and framework involving identifying, assessing, and managing risks in the context of the Group's values, objectives, and strategies. The Board oversees the implementation of the risk management system and reviews its effectiveness. Financial risks identified include interest rate risk, credit risk, liquidity risk, and foreign currency risk. Risk identification and evaluation consider historical data, forward-looking economic conditions, and credit risk exposure using tools such as a provision matrix for expected credit losses. The Board regularly reviews undiscounted cash flow forecasts and actual cash flows to monitor liquidity risk and decides on capital raising accordingly. | The Group has a formal risk management policy and framework involving identification, assessment, and management of risks in the context of the Group's values, objectives, and strategies. The Board oversees the implementation of the risk management system and reviews its effectiveness. The Group seeks to minimize exposure to risks impacting financial performance, growth, and survival in a cost-effective manner. Credit risk is assessed using a provision matrix based on historical default rates and forecast economic conditions. Expected credit losses are calculated using this matrix and forward-looking factors. Financial risks such as interest rate risk, credit risk, liquidity risk, and foreign currency risk are identified and managed with specific policies, including placing cash in term deposits and maintaining foreign currency bank accounts. The Group conducts annual impairment assessments for intangible and other assets, considering external factors and estimating recoverable amounts using discounted future cash flows. |
| Control activities | Control activities include policies and procedures to manage capital structure and financial risks, such as placing cash and cash equivalents on term deposits with approved banks to reduce credit risk, and using foreign exchange forward contracts on an ad hoc basis to manage foreign currency risk. The Group applies compliance frameworks including the Corporations Act 2001, Australian Accounting Standards, and International Financial Reporting Standards. The Board Charter, Audit and Risk Committee Charter, Code of Conduct, Whistleblower Policy, Diversity Policy, Share Trading Policy, Environment Policy, and Remuneration Policy form part of the governance framework. Operational procedures include monitoring trade receivables aging and provisioning for expected credit losses based on a provision matrix. The Group also manages interest rate risk by locking portions of cash into term deposits based on cash flow forecasts. | PolyNovo implements control activities through corporate governance policies aligned with the ASX Corporate Governance Council's eight Principles of Good Corporate Governance. These include the PolyNovo Board Charter, Commercial Code of Conduct, Whistle-blower Policy, Gender Diversity Policy, Share Trading Policy, Environment Policy, Modern Slavery Statement, Audit and Risk Committee Charter, Market Disclosure Protocol, Communications Policy, Risk Management Policy, Health and Safety Policy, and Remuneration and Nomination Committee Charter. Financial controls include placing cash in term deposits with the National Australia Bank, monitoring receivables and payables, and managing credit risk through expected credit loss provisions. The Group applies accounting policies consistent with Australian Accounting Standards and IFRS, with management judgments and estimates disclosed. Provisions are recognized based on present obligations and reliable estimates. Share-based payments and senior management remuneration policies link performance to compensation. The Group also maintains indemnification and insurance policies for Directors and Officers. |
| Monitoring mechanisms | Monitoring mechanisms include the Board of Directors and its committees, notably the Audit and Risk Committee chaired by a Non-Executive Director, which meets regularly (4 meetings in FY24). The Board reviews the effectiveness of the risk management system and capital management. The external auditor, Ernst & Young, performs audits in accordance with Australian Auditing Standards, communicating significant audit findings and any internal control deficiencies to the directors. The Board receives declarations from the CEO and CFO regarding financial reports and internal controls. The Board also monitors liquidity risk through regular review of cash flow forecasts and actual cash flows provided by management. | The Board of PolyNovo oversees the risk management system and reviews its effectiveness. The Audit and Risk Committee monitors the integrity of corporate reports and internal controls. The external auditor, Ernst & Young, conducts audits in accordance with Australian Auditing Standards, communicating significant audit findings and any deficiencies in internal control to the directors. The auditor assesses risks of material misstatement and tests the operating effectiveness of revenue controls. The Group monitors trade receivables continuously to manage credit risk exposure. Annual impairment assessments of assets are conducted, and financial risk exposures are analyzed regularly. The Board reviews capital management and financial risk policies. Committees such as the Remuneration and Nomination Committee oversee compensation and governance practices. The Group also engages third-party consultants for environmental waste management monitoring. |
| Identified material weaknesses or deficiencies | N/A | N/A |
| Effectiveness | Management and the Board assess internal controls as adequate to provide a true and fair view of the financial position and performance, complying with Australian Accounting Standards and the Corporations Act 2001. Directors have provided declarations required under the Corporations Act regarding the financial year ended 30 June 2024. The external auditor's report does not identify any material weaknesses or significant deficiencies in internal control. The Board and Audit and Risk Committee conclude that the internal control system is effective and sufficient for the preparation of financial reports free from material misstatement. | Management is responsible for establishing and maintaining internal control necessary to prepare financial reports free from material misstatement. The Board reviews governance policies referencing ASX Principles to ensure ethical and responsible conduct, integrity in reporting, and risk management. The external auditor obtained sufficient appropriate audit evidence and found no significant deficiencies in internal control. The auditor's report expresses an unqualified opinion on the financial report. The Group's risk management system is reviewed for effectiveness by the Board. The Group's financial risk management policies and controls are designed to minimize exposure to risks impacting financial performance. No material uncertainties or weaknesses were reported. Overall, the internal control system is assessed as adequate and effective in supporting the preparation of reliable financial reports and compliance. |


# Section 6: Future Outlook

## S6.1: Strategic Direction

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Mergers and Acquisition | The 2024 annual report does not mention any mergers and acquisitions strategy, acquisition targets, bolt-on deals, or strategic investments. The company remains open to tactical opportunities created by surgeons across geographical clusters but no specific M&A plans or deal values are disclosed. | N/A |
| New technologies | The company is advancing technology innovation initiatives including expanding the product range of NovoSorb BTM and NovoSorb MTX with additional sizes and thicknesses, and developing new products under the NovoSorb SynTrix platform for plastics and reconstructive devices. They are investing in R&D to support new product development and faster commercialization, including particulate variants of NovoSorb MTX for soft tissue reconstruction. The company is also collaborating with Beta Cell Technologies on a novel Intracutaneous Ectopic Pancreas implant for Type 1 Diabetes, with promising early trial results expected to be published in late 2024. They have established a new co-located R&D lab and innovation centre and received a Victorian Government grant of A$2 million for R&D facilities expansion. Innovation programs include surgeon-led insights driving new indications and applications, and a professional education program 'Science of Complex Wound Management' to train clinicians. The company is open to alliances to co-develop, commercialize, or distribute new products leveraging their core NovoSorb technology platform. | PolyNovo is focused on expanding its proprietary NovoSorb resorbable polymer platform, which supports a range of medical applications including dermal repair, soft tissue replacement, and regeneration of soft and hard tissues. In 2023, the company launched NovoSorb MTX, a major product innovation for soft tissue regeneration, which received FDA 510(k) clearance on 19 September 2022. NovoSorb MTX expands the addressable market in the U.S. by an estimated AU$500 million. The company is also developing implantable applications such as surgical mesh products for hernia repair, abdominal wall reconstruction, and post-mastectomy breast reconstruction. PolyNovo is supplying NovoSorb BTM to Beta-Cell Technologies for use as a dermal deposit in Type 1 diabetes treatment trials. R&D investments include clinical trials for burns, diabetic foot ulcers, and chronic wounds, with ongoing FDA 510(k) submissions planned to expand the NovoSorb BTM product range. The company is also investing in manufacturing capabilities to support increased production volumes and new product development. |
| Organisational Restructuring | The company has expanded and restructured its executive team with several new appointments in 2023-24 including a Chief Medical Officer, Chief People Officer, President Asia Pacific, and General Counsel & Company Secretary, as well as a promotion to President North America. The remuneration strategy has been comprehensively reviewed and updated to align with strategic priorities, including benchmarking key roles against industry data, refreshing STI plan terms and KPIs, and designing a new Long-Term Incentive Plan. The company focuses on attracting and retaining talent with market competitive rewards linked to performance, and supports employee development through online learning platforms, world-class conferences, and performance planning programs. Diversity and inclusion are emphasized with updated policies and targets for female representation. Health and safety initiatives have been enhanced with zero lost time injuries in FY24. Employee numbers increased from 218 to 254, reflecting investment in human capital to support global growth. | PolyNovo increased its total employees from 152 to 218 in FY23, with significant expansion of sales teams in established markets such as the U.S. and onboarding of sales professionals in new markets including Hong Kong and India. The company appointed key senior management personnel during the year, including a new CEO, Chief Technical and Scientific Officer, and Chief Information Officer. Talent management initiatives include a strong focus on learning and development, with access to an online learning platform, appraisal and development programs, targeted educational programs, and mentorship. The company has implemented a short-term and long-term incentive compensation policy for senior managers to align performance with shareholder interests. Organizational structure includes ten wholly owned subsidiaries across multiple countries to support global operations. Capital raising of $53 million in November 2022 supports expansion plans, including design and construction of a new manufacturing facility expected to be operational in Q1 FY26, which will increase production capacity approximately fivefold. |


## S6.2: Challenges and Uncertainties

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Economic challenges such as inflation, recession risks, and shifting consumer behavior that could impact revenue and profitability. | PolyNovo Limited faces economic challenges including inflation and rising interest rates which have increased costs across all markets, notably wages and salaries. The company manages interest rate risk through term deposits and cash flow forecasting to mitigate cost pressures. Foreign currency risk is significant due to expenses in multiple currencies (USD, GBP, EUR, NZD), and the company uses cash holdings and forward contracts to manage this exposure. Liquidity risk is managed by the Board through cash flow monitoring and ensuring sufficient funds to meet liabilities. The company acknowledges unpredictability in revenue and sales due to the nature of its product category. Additionally, the company is exposed to credit risk from trade receivables, which have grown with increased commercial sales, but this risk is monitored and considered not significant. The company also faces risks related to concentration of manufacturing at a single site, which could disrupt supply and impact financial performance. Overall, macroeconomic factors such as inflation, interest rate fluctuations, foreign exchange volatility, and cost increases present ongoing uncertainties that could impact revenue and profitability. | PolyNovo faces economic challenges including inflation and rising interest rates which have increased costs across all markets, notably wages and salaries. The Group manages foreign currency risk due to exposure to multiple currencies (USD, NZD, EUR, CAD, INR, GBP, SGD) which can result in exchange losses or gains impacting financial performance. Liquidity risk is present if the Group encounters difficulty raising funds to meet financial liabilities, with the Board actively monitoring cash flow forecasts and capital requirements. The Group updates cash flow forecasts to manage the impact of higher inflation and interest costs. Economic uncertainties also arise from the speculative nature of investment in research and development projects, with no guarantee of funding or successful commercialisation. The Group's financial performance is sensitive to fluctuations in interest rates and foreign exchange rates, with potential adverse effects on loss and equity. Additionally, macroeconomic factors such as market conditions and cost pressures are managed through discretion in cash outflows and capital structure optimization. The Group's exposure to credit risk is monitored but considered not significant. Overall, economic challenges include managing cost pressures, currency fluctuations, liquidity, and funding uncertainties in a volatile macroeconomic environment. |
| Competitive pressures from both established industry players and new, disruptive market entrants that the company faces. | PolyNovo Limited faces competitive pressures from increased competition that risks loss of market share, especially if the company fails to innovate beyond its current core offerings. There is a risk that medical advancements could lead to alternative products or treatments superseding PolyNovo's products. The company actively reviews product development plans considering market dynamics, competitive landscape, and technological advancements, supported by a dedicated R&D team. The company is the category leader in burn procedures in several markets but continues to expand into new indications and geographies to maintain and grow its market position. The addition of new products and partnerships, such as SUPRATHEL distribution, aims to strengthen its competitive position. The company also faces industry dynamics including regulatory approvals and the need for clinical evidence to support product adoption. Technological disruption and market competition require ongoing investment in innovation, sales force expansion, and global market penetration to sustain growth and defend market leadership. | PolyNovo operates in a competitive environment with pressures from established industry players and new market entrants. The rapid advancements in technology pose risks including uncertainty of patent protection and proprietary rights, which may affect the Group's ability to protect its innovations and maintain market position. The Group faces competitive threats in expanding markets such as the U.S., UK, Europe, India, Canada, and Asia, where it is actively growing sales and entering new territories. Market competition is intensified by the need to secure regulatory approvals (e.g., FDA 510(k) clearances) and to build clinical evidence to support product adoption. The company is expanding its product portfolio and seeking partnerships to accelerate growth and address diverse clinical needs, indicating a dynamic industry landscape with technological disruption. The Group's strategy includes leveraging surgeon acceptance and clinical education to maintain competitive advantage. The need to continuously innovate and expand indications for its products (NovoSorb BTM, MTX, SynPath) reflects ongoing competitive pressures. Additionally, the Group must manage risks related to intellectual property, regulatory approvals, and market penetration against competitors and disruptive entrants in the regenerative medical device sector. |


## S6.3: Innovation and Development Plans

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| R&D investments, with a focus on advancing technology, improving products, and creating new solutions to cater to market trends | PolyNovo Limited increased its research and development expenses by 47.1% to $10.9 million in FY24, reflecting heightened activity in research and commercialisation of new products. The company focuses on advancing its patented NovoSorb bioabsorbable polymer technology, developing new product iterations including thicker and thinner versions of NovoSorb BTM and NovoSorb MTX, and expanding into new clinical indications such as hernia repair and plastic and reconstructive devices. Investment includes building a new co-located R&D lab and innovation centre, supported by a Victorian Government grant of A$2 million for R&D facilities expansion. The company also collaborates with third parties like Beta Cell Technologies for novel applications such as a dermal beta-cell implant for Type 1 diabetes. Depreciation and amortisation related to R&D assets increased, and the company is preparing regulatory submissions for new product variants. The BARDA pivotal trial for severe thermal burns, funded with USD$25 million, is a key R&D initiative nearing completion, supporting FDA PMA approval efforts. Construction of a third manufacturing facility designed for scale, flexibility, and automation is underway to support increased production capacity and innovation commercialization. | In FY23, PolyNovo increased research and development expenses by 29.3% to $7.43 million, reflecting heightened activity in research and commercialisation of new products. The company invested in expanding its R&D and clinical teams to gain insights, evidence, and develop new solutions for clinicians and patients. Key R&D initiatives included advancing the NovoSorb technology platform, focusing on expanding the product range of NovoSorb BTM and NovoSorb MTX, and developing implantable applications such as hernia repair and breast reconstruction devices. Clinical trials progressed with enrollment in the U.S. BARDA pivotal trial for full thickness burns (64 of 120 patients enrolled) and a 138-patient randomized control trial for diabetic foot ulcers using NovoSorb SynPath. PolyNovo also supported third-party R&D by supplying NovoSorb BTM for BetaCell Technologies' dermal beta-cell implant program targeting Type 1 diabetes. Capital investments included cleanroom upgrades and new manufacturing equipment, partly funded by a $500k Victorian State Government grant. The company is designing a new manufacturing facility to significantly increase production capacity, expected operational by Q1 FY26. Additional FDA 510(k) submissions for product range expansion are planned for late 2023 and 2024. |
| New product launches, emphasizing the company's commitment to continuously introducing differentiated products | In FY24, PolyNovo launched the full market release of NovoSorb MTX in the U.S., a product complementing NovoSorb BTM for complex wound management, including use by vascular surgeons for diabetic patients. NovoSorb MTX received FDA 510(k) clearance in September 2022, with additional 510(k) submissions planned to expand the product range. The company is expanding the NovoSorb BTM product line with larger sizes and varied thicknesses to address broader clinical applications. The addition of SUPRATHEL, an epidermal skin substitute with strong clinical evidence and market leadership in Europe, to the product portfolio in Australia, New Zealand, and the U.K. enhances the continuum of complex wound care solutions. Market differentiation strategies include surgeon-led innovation, professional education programs like 'Science of Complex Wound Management,' and leveraging clinical insights to drive new indications and applications. The company is also developing hernia repair products under the NovoSorb SynTrel brand, with regulatory processes planned to start in FY26. Geographic expansion and new registrations in multiple countries support product adoption and market penetration. | In 2023, PolyNovo launched NovoSorb MTX, a major product innovation for soft tissue regeneration, receiving FDA 510(k) clearance in September 2022 and commencing limited market release in the U.S. in April 2023. NovoSorb MTX complements NovoSorb BTM by providing a foam-only product without a sealing membrane, suitable for partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, and surgical and trauma wounds, expanding the addressable U.S. market by an estimated AUD $500 million. The company successfully entered new markets including Hong Kong, India, Canada, Spain, and France, with early impressive sales and adoption. NovoSorb BTM continued to grow strongly with 58.3% revenue growth, supported by surgeon acceptance and expanded clinical applications beyond burns into trauma, plastic reconstruction, and chronic wounds. The company also launched NovoSorb SynPath, currently in clinical trials for diabetic foot ulcers, aiming for insurance reimbursement in the U.S. outpatient market. Market differentiation strategies include leveraging clinical evidence, surgeon-led innovation, and expanding product indications through ongoing clinical trials and regulatory approvals. |
